Program
solrikitug
Also written as “NSI-8226”, “Solrikitug” and “MK-8266 TID, 2.4 mg”.
Its studies are mostly in Hypertension · Asthma · Eosinophilic Esophagitis · Dermatitis, Atopic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 40 open or running | phase 1since Dec 3, 2009 | Dec 3, 2009 | none ahead |
| Uniquity One (UNI) | 31 open or running | phase 2since Jul 3, 2024 | Jul 3, 2024 | Apr 30, 2027phase 2 · NCT06598462 |
Also a collaborator on its studies: devpro-biopharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2009First study: phase 1 study in HypertensionNew to MerckMerck · NCT01025791 · 25 enrolled
- Mar 26, 2010Phase 1 study in HypertensionMerck · NCT01096160 · 40 enrolled
- Nov 15, 2010Phase 1 study in HypertensionMerck · NCT01263314 · 16 enrolled
- Nov 19, 2012Phase 1 study in Dermatitis, AtopicMerck · NCT01732510 · 65 enrolled
- Jul 3, 2024Uniquity One (UNI)'s first study: phase 2 study in AsthmaNew to Uniquity One (UNI)Uniquity One (UNI) · NCT06496607 · 145 enrolled · United States
- Sep 13, 2024Phase 2 study in Eosinophilic EsophagitisUniquity One (UNI) · NCT06598462 · 184 enrolled · United States, Australia, Belgium and more
- Feb 26, 2025Phase 1 study in HealthyUniquity One (UNI) · NCT06868082 · 32 enrolled · Australia
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Eosinophilic EsophagitisUniquity One (UNI) · NCT06598462
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06868082Healthy · Australia | 1 | Completed | Uniquity One (UNI) | Feb 2, 2026 | 32 |
| NCT06598462Eosinophilic Esophagitis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Uniquity One (UNI) | Apr 30, 2027 | 184 |
| NCT06496607Asthma · United States | 2 | Completed | Uniquity One (UNI) | Jul 6, 2026 | 145 |
| NCT01732510Dermatitis, Atopic | 1 | Terminated | Merck | Oct 20, 2014 | 65 |
| NCT01263314Hypertension | 1 | Completed | Merck | Feb 1, 2011 | 16 |
| NCT01096160Hypertension | 1 | Completed | Merck | Nov 1, 2010 | 40 |
| NCT01025791Hypertension | 1 | Completed | Merck | May 14, 2010 | 25 |
How it is read
Names in the registry
- “NSI-8226”, 3 entries
- “Solrikitug”, 2 entries
- “MK-8266 TID, 2.4 mg”, 2 entries
- “Solrikitug Low Dose”, 1 entry
- “Solrikitug Mid Dose”, 1 entry
Codes read as this program: MK8266.
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Asthma, 1 study
- Eosinophilic Esophagitis, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.